Evergreening
Evergreening is a label used by the generics industry for patent strategies facilitating switches to follow-up inventions or second-generation products, as recorded in the European Commission's 2009 Pharmaceutical Sector Inquiry1. The European Commission's 2009 inquiry notes that these terms are not defined in patent legislation1.
The European Commission's 2009 inquiry records generics' criticism of patent strategies supporting switches to follow-up inventions or second-generation products in paragraph 4801. The European Commission's 2009 inquiry also records originators' view that incremental innovations may meet unmet or differentiated consumer needs in paragraph 9931.
Two viewpoints in the same report
| Viewpoint | What the report records |
|---|---|
| Generics industry | The European Commission's 2009 inquiry, paragraph 480, reports the evergreening criticism of strategies facilitating switches to follow-up inventions or second-generation products1 |
| Originator companies | The European Commission's 2009 inquiry, paragraph 993, reports their view that even small incremental innovations may address unmet or differentiated consumer needs1 |
The label in a US consultation
The USPTO's 2022 notice at 87 FR 67019 included remaining open to discussions of the FDA's concerns about practices referred to as evergreening, patent thickets, and product hopping2.
The USPTO's 2022 notice sought public input on collaboration initiatives between the USPTO and FDA2.
What the Indian Supreme Court said
In Novartis AG v. Union of India (2013), paragraph 191, the Supreme Court of India held that the beta crystalline form of Imatinib Mesylate at issue did not meet section 3(d)3.
In the same paragraph, the Court expressly said this did not mean section 3(d) bars patent protection for all incremental inventions of chemical and pharmaceutical substances3.
Questions people ask
Check a product
FTO Search AI Agent
An AI agent that finds in-force patents that could read on your product, with a claim chart for each one.
Run FTO SearchIs evergreening itself a defined statutory patent category?
No, the European Commission's 2009 inquiry uses industry terminology subject to its express caveat that these concepts are not defined in patent legislation1.
Does every incremental pharmaceutical invention fail section 3(d)?
No, paragraph 191 of Novartis expressly says section 3(d) does not bar patent protection for all incremental inventions of chemical and pharmaceutical substances3.
What do originator companies say about follow-on products?
The European Commission's 2009 inquiry, paragraph 993, records their view that even small incremental innovations may produce products meeting unmet or differentiated consumer needs1.
How it connects
Go from the term to the task
Read how the method works, run it on your own product or idea, then try a free tool.
- 01 / How-toHow to run a freedom-to-operate analysisScope, search, claim review and the report counsel will ask for.Read
- 02 / AI agentFTO Search AI AgentAn AI agent that finds in-force patents that could read on your product, with a claim chart for each one.Run it